"I am creating a world #Immune2Cancer by developing novel immunotherapy treatment strategies for women with gynecologic cancers, including cervical, endometrial, and ovarian," shares CRI Clinical Accelerator Investigator @DmitriyZamarin@MSKCancerCenter: https://t.co/PIXAcBDZLl
Late breaking at #SGOMtg: In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than chemotherapy alone. https://t.co/dTyV1zTO0I